Together, these findings and the striking regional overlap of glucose hypometabolism and tau deposition in AD brains suggest that inhibition of the OGA enzyme is a potential therapeutic approach to target tau accumulation in AD. The gene discussed is MAPT; the disease is Alzheimer disease.